Matteo Santoni

@aron_project at #EAU26 with the fantastic oral presentation by @vmollica7 @EUplatinum @Uromigos @urotoday @MatteoSantoniMD

Belzutifan is changing RCC scenario. From VHL disease to adjuvant and metastatic disease. In this review, we analyze Belztufian's career and discuss his promising future in RCC field. I hope you find it useful! pubmed.ncbi.nlm.nih.gov/41636289/ @MatteoSantoniMD

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study nature.com/articles/s4139… Study reports real-world outcomes of enzalutamide (ENZA) in 424 metastatic hormone-sensitive #ProstateCancer (mHSPC) patients from the ARON-3 study. Median treatment duration was 31.8 months, with median overall survival not reached. PSA90 and ultra-low PSA0.2 responses were achieved in 76% and 59% of patients, respectively, correlating with longer survival. ENZA demonstrated effectiveness across metastasis types and disease volumes, with grade 3–4 adverse events in 9–10% of patients, supporting its safety and clinical benefit. Thomas Büttner @LauBernalOnc @JaviMolinaC @nataliagandur @BourlonMaite @DrYukselUrun @SScagliarini_ @APoprach @lihaoran @AlessandraMosc5 @fmassari79 @EAntonarakis @MatteoSantoniMD @montypal @apolo_andrea @PGrivasMDPhD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @brian_rini @AOmlin #OncoAlertAF @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

Results from the ARON-3 study, led by Drs. @EAntonarakis & @MatteoSantoniMD, confirm the effectiveness and safety of enzalutamide in metastatic hormone-sensitive #prostate cancer patients. 📖 Read the full story: go.nature.com/49vXX0R

⚡️ Real-world ARON-2EV: enfortumab vedotin after platinum + pembrolizumab in mUC achieves mOS 12.3 months and ORR 45%. Prior pembro response predicts better EV outcomes, but activity persists even after PD. #BladderCancer @EUplatinum eu-openscience.europeanurology.com/article/S2666-…

NEW in @EUOpenScience: Large real-world study (ARON-2EV) confirms efficacy of enfortumab vedotin in metastatic #urothelialcarcinoma after platinum & pembrolizumab. ✅ mOS: 12.3 mo ✅ ORR: 45% EV worked even after PD on prior pembrolizumab (ORR 35%). #BladderCancer @ONCOassist

Just out at @MetastasisRS journal another timely and very helpful RWD including 2k mUC patients of @aron_project . Congrats @MatteoSantoniMD @fmassari79 @JaviMolinaC @Martin_AngelMD @SoaresAndrey @drenriquegrande @shilpaonc

Congrats @fsabino_onco @SpiessPhilippe @MatteoSantoniMD on this excellent editorial in @EUplatinum Great to see progress in penile cancer with checkpoint inhibitors! @AndreaNecchi @sonpavde

Are better days ahead in penile cancer? Just out in @EUplatinum @SpiessPhilippe @MatteoSantoniMD europeanurology.com/article/S0302-…

📢 Out now one of the largest real-world cohorts on adjuvant pembrolizumab for RCC by @aron_project 🔬 An important step forward in understanding how to optimize the management of renal cell carcinoma in real-life settings. @IntKidneyCancer @OncoAlert @Uroweb

The Eurasia team 🇯🇵 🇨🇳 🇦🇺 🇳🇱 🇪🇸 🇮🇳 Educational video for the Uromigos cup 🏆 ♥️ @crisuarez08 🇪🇸 🇪🇸 🇪🇸 🇪🇸 team is 8 points ahead!!! Here the team discusses recent developments from ESMO which you may not have seen!#UromigosLive @OncoAlert

Just out! Patients who permanently discontinue immunotherapy treatment, due to SirAE, after completing at least 3 months, have the same OS as patients who continue treatment continuously! This is the largest RWE study in this RCC setting! Congrats to ARON! onlinelibrary.wiley.com/doi/10.1002/ij…

CheckMate-9ER: cosa emerge dall’osservazione real life di ARON-1 su nivolumab + cabozantinib nel carcinoma renale metastatico e come questi dati influenzano la selezione del trattamento di prima linea del mRCC? Lo abbiamo chiesto a Matteo Santoni a#ESMO25 shorturl.at/CnufA

Carcinoma prostatico ormono-sensibile metastatico: quali conferme arrivano dalla real life sull’utilizzo di darolutamide + terapia di deprivazione androgenica (ADT) + docetaxel testato nel trial ARASENS? Lo abbiamo chiesto a Francesco Massari a #ESMO25 oncoinfo.it/congressi/mhsp…

Quali sono le RWE da ARON-2EV su enfortumab vedotin e come confermano o modificano il posizionamento sequenziale di enfortumab vedotin dopo mantenimento con avelumab nel carcinoma uroteliale avanzato? Lo abbiamo chiesto a Daniele Santini a #ESMO25 oncoinfo.it/congressi/enfo…

Quali RWE emergono da ARON-3 sul confronto tra Lu-177 PSMA e cabazitaxel, e cosa suggeriscono circa le strategie di trattamento del carcinoma prostatico resistente alla castrazione? Lo abbiamo chiesto a Matteo Santoni, che abbiamo incontrato a #ESMO25 oncoinfo.it/congressi/trat…

Efficacy of EV After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma. Out now on @EurUrolOpen the RWE by @aron_project

Sarcomatoid Differentiation in RCC: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors. Now on @JCOGO_ASCO our work by @aron_project @IKCCorg @IntKidneyCancer @Uromigos @Unibo @MattRosellini @vmollica7 @MatteoSantoniMD

#ESMO25 | Where is the ARON Group heading next? Francesco Massari shares his tips. Catch the full feature and all other essential interviews with the ARON Group in the special post-ESMO OncoInfo edition!

@aron_project is more than an amazing collaborative research working group. It is a family. Thanks for this incredible journey. @MatteoSantoniMD @fmassari79 @drenriquegrande @JaviMolinaC @SoaresAndrey @vmollica7